tiprankstipranks
Trending News
More News >

Rhythm Biosciences Unveils Enhanced Colorectal Cancer Risk Model

Story Highlights
Rhythm Biosciences Unveils Enhanced Colorectal Cancer Risk Model

Don’t Miss TipRanks’ Half-Year Sale

Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an announcement.

Rhythm Biosciences Ltd has announced the publication of a peer-reviewed study in PLoS One, detailing an enhanced colorectal cancer risk assessment model. This new model, an extension of the geneType™ product line, incorporates sex-specific and additional risk factors, outperforming existing models. The study, which used data from nearly 400,000 individuals in the UK Biobank, highlights the model’s superior predictive ability and its potential for commercial clinical applications. The innovation underscores Rhythm’s commitment to advancing cancer risk prediction and improving stratified screening, positioning the company as a leader in predictive diagnostics technology.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest stages, thereby reducing the global cancer burden. Rhythm Biosciences collaborates with global partners to commercialize and distribute their solutions, including the ColoSTAT® Test-Kit for colorectal cancer detection.

Average Trading Volume: 222,159

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$18.29M

See more insights into RHY stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1